Novartis, Siemens to develop blood tests for multiple sclerosis – Fierce Biotech

Earlier this year, Novartis presented data showing its multiple sclerosis drug Mayzent could be effective when given early for secondary progressive MS. However, the condition is often diagnosed late as symptoms become more apparent. (Ildar Imashev/Getty Images)

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline.

To start, the companies will design and develop a biomarker test aimed at neuroscience programs, and multiple sclerosis specifically—a treatment area that they expect to expand into a $23.5 billion global market by 2025.

The initial immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, which are linked to nerve cell injury and a variety of neurological conditions including MS.

Click here to read full article

Font Resize